In the telehealth sector, Hims & Hers (HIMS) is presented as the superior investment right now due to its more stable cash-pay business model. This model avoids the significant risk of insurance claim denials that is currently hurting competitor LifeMD (LFMD) in the popular GLP-1 weight-loss drug market. LFMD recently experienced a sharp stock drop after cutting its revenue guidance, highlighting the challenges in its business. With a stronger guided revenue growth of 45%, HIMS offers a more predictable and robust outlook. A key potential catalyst for LFMD to watch for is the sale of its slow-growing legacy business, WorkSimply.

LifeMD (LFMD)

• The stock dropped -32% in after-hours trading following its earnings report and conference call. The speaker notes that management seemed to be in a "pretty bad mood."
• Guidance Cut: The primary reason for the drop was a downward revision of full-year revenue guidance. The midpoint was lowered by approximately 8%, from $271.5 million to $252.5 million.
• Business Segment Challenges:
  • Erectile Dysfunction (ED) - RexMD: This segment experienced significant headwinds.
    • Customer Acquisition Cost (CAC) went "through the roof" and customer retention fell.
    • The speaker attributes this to aggressive advertising campaigns from competitors, specifically mentioning private players like BlueChew.
    • Management stated on the call that this issue has since been "resolved."
  • GLP-1 Weight Loss Drugs: The company is facing major issues with its insurance-based model.
    • LifeMD only offers branded GLP-1s (like Ozempic and tirzepatide) and does not offer compounded versions.
    • They rely on submitting claims to commercial insurance payers, but these claims are being denied in "droves."
    • When a claim is denied, LifeMD has to issue a refund to the customer, resulting in a financial loss for the company.
• Positive Developments:
  • Profitability: The company is expected to be adjusted EBITDA positive for the full year 2025, with a target of $16 million. It is also currently cash flow positive.
  • LifeMD Plus Subscription: This $19/month subscription plan is seen as a major positive and potential differentiator.
    • It is reportedly adding 50 new customers per day.
    • The speaker describes it as the "Netflix of doctors," offering broad access to primary and urgent care via chat or video.
• Legacy Business Drag:
  • The company owns a legacy SaaS business called WorkSimply.
  • This business is growing at only 2% and is considered a "dead weight" that drags down the company's overall reported revenue growth.
  • The speaker believes that selling WorkSimply would create a "cleaner story for Wall Street" and that the stock will pop once the sale happens.

Takeaways

• Short-Term Bearish: The significant guidance cut and challenges in two key growth segments (ED and GLP-1s) justify the -32% stock drop, according to the speaker.
• Key Risk - Insurance Model: The reliance on insurance reimbursement for GLP-1s is a major headwind. The high rate of claim denials creates revenue uncertainty and direct financial losses. The speaker strongly prefers a cash-pay model.
• Potential Catalysts:
  • Sale of WorkSimply: A sale of this slow-growing legacy business could simplify the investment story and unlock value.
  • Growth of LifeMD Plus: The rapid adoption of their $19/month subscription service could become a core, stable, and high-margin revenue stream, differentiating them from competitors.
• Long-Term View: The speaker is a long-term investor and is holding the stock, but acknowledges the current challenges are significant. The company is profitable on an adjusted EBITDA basis and cash flow positive, which provides a floor for the business.

Hims & Hers Health, Inc. (HIMS)

• HIMS is presented as the primary competitor and benchmark for LifeMD.
• Business Model Advantage: The speaker strongly favors the HIMS model because it is primarily cash-pay.
  • This model avoids the "bad surprises" of insurance claim denials that LifeMD is currently facing with its GLP-1 business.
  • Cash-pay allows for faster "velocity of the money," meaning the company can reinvest its earnings more quickly without waiting weeks for insurance decisions.
• GLP-1 Strategy: HIMS has the ability to offer compounded GLP-1s, which LifeMD does not. The speaker believes HIMS is responsible in its compounding practices and that this flexibility, combined with its cash-pay model, is a superior strategy.
• Growth Outlook: HIMS looks "pretty darn good" in comparison, guiding for 45% revenue growth in 2025.
• ED Market Impact: HIMS also experienced a slowdown in its ED business, which the speaker believes is why they only maintained, rather than raised, their guidance in their last report.

Takeaways

• Currently the Better Play: The speaker is "torn" but leans towards HIMS as the better play right now.
• Lower Risk Model: Its cash-pay focus insulates it from the insurance reimbursement problems plaguing LifeMD, making its revenue stream more predictable and reliable.
• Stronger Growth: HIMS is demonstrating a significantly higher growth rate (45% guided for 2025) compared to LifeMD's newly revised guidance.

Key Investment Themes

Cash-Pay vs. Insurance Model

• A central theme is the superiority of a cash-pay business model in the telehealth space.
• Cash-Pay (HIMS): Seen as a major advantage. It leads to predictable revenue, no risk of claim denials, and faster cash conversion cycles, allowing for quicker reinvestment into the business.
• Insurance-Reliant (LifeMD for GLP-1s): Presented as a significant risk. The process is slow, and insurance companies are incentivized to deny expensive claims like GLP-1s, leading to revenue reversals and customer churn for the provider.

GLP-1 Market Dynamics

• The GLP-1 weight loss drug market has brought hype and volatility to these stocks.
• The speaker notes that without the GLP-1 story, a stock like LFMD would likely not have experienced such a dramatic -32% single-day move.
• This highlights the risk for investors: while GLP-1s offer massive growth potential, they also introduce significant volatility and business model challenges (e.g., the payer issue).

Erectile Dysfunction (ED) Market Competition

• The ED market is facing intense competition, likely from private companies running aggressive advertising campaigns (e.g., BlueChew).
• This competition has driven up customer acquisition costs and hurt customer retention for both LifeMD (RexMD) and HIMS, impacting a core and previously stable part of their businesses.